<DOC>
	<DOCNO>NCT00421369</DOCNO>
	<brief_summary>In project aim refine indication use thyroid hormone - T3 patient suffer depression . We aim identify sub-group patient likely respond T3 establish time treatment course T3 add . The result project could significant , direct clinical implication .</brief_summary>
	<brief_title>Augmentation Antidepressant Action Sertraline With Triiodothyronine ( T3 ) Reboxetine : Clinical Efficacy , Adverse Effects Predictors Response .</brief_title>
	<detailed_description>The lifetime risk major depressive disorder ( MDD ) 15 % general population . Current treatment approach emphasize achievement remission . Remission imply virtual absence depressive symptom associate good function well overall prognosis response , usually define 50 % reduction symptom severity . Sixty percent patient treat optimally antidepressant remain un-remitted need additional treatment . A potentially effective under-exploited strategy augment antidepressant effect concurrent administration thyroid hormone , triiodothyronine ( T3 ) . We previously demonstrate clinical efficacy safety T3 administer concurrently SSRI , sertraline , context randomize , double-blind placebo-controlled trial . Although patient euthyroid , remission rate significantly high sertraline plus T3 group associate significantly low baseline T3 value significant decrease serum thyroid stimulate hormone ( TSH ) value course treatment . The study aim : - Delineate sub-population depressed patient treated sertraline , likely respond T3 augmentation basis thyroid function genetic variation thyroid pathway gene . - Investigate appropriate timing addition T3 . - Assess efficacy reboxetine , specific noradrenaline reuptake inhibitor , supplement treatment un-remitted patient . The result study could significant , direct clinical impact pharmacological treatment MDD .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>1 . Diagnosis Major Depressive Episode ( MDE ) context MDD accord DSMIV criterion , without psychotic feature . 2 . Hamilton Depression Scale ( 21 item , HAMD ) total &gt; 16 item 1 ( depressed mood ) &gt; 2 . 3 . Age 1870 year . 4 . Male female . 5 . Competent willing give write informed consent . 1 . Clinical hyper hypothyroidism thyroid illness . 2 . Neurological medical illness may impact upon study limit prescription study medication . 3 . Significant suicidal risk [ HAMD item 3 ( suicide ) &gt; 2 ] . 4 . Comorbidity Psychotic Disorder , Bipolar Disorder , Post Traumatic Stress Disorder ( PTSD ) , Eating Disorder . 5 . Lifetime history substance alcohol dependence abuse precede 12 month . 6 . Treatment antidepressant , sertraline , current episode . 7 . More one antidepressant trial augmentation treatment current episode . 8 . Length current episode &gt; 12 month 9 . Female subject pregnant lactate use adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Triiodothyronine ( T3 )</keyword>
	<keyword>Thyroid Function</keyword>
	<keyword>Augmentation</keyword>
	<keyword>Thyroid pathway gene</keyword>
</DOC>